紫杉醇联合顺铂化疗用于晚期食道癌治疗中的临床效果分析.docVIP

精品论文 参考文献 紫杉醇联合顺铂化疗用于晚期食道癌治疗中的临床效果分析 贺丹 核工业四一六医院 四川成都 610000 【摘 要】目的：探讨晚期食道癌患者经紫杉醇联合顺铂化疗临床疗效。方法：对照组给予顺铂联合5-氟尿嘧啶化疗，研究组给予顺铂联合紫杉醇化疗。记录两组晚期食管癌患者临床疗效、化疗相关不良反应发生情况。结果：两组晚期食道癌患者经上述相应方案完成化疗后，研究组总有效率（75.56%）显著高于对照组（55.56%）（Plt;0.05）；研究组化疗相关不良反应发生情况与对照组对比并无显著差异（Pgt;0.05）。结论：对晚期食管癌患者给予紫杉醇联合顺铂化疗可显著提高其临床疗效，有利于保障患者生活质量及生命安全。 【关键词】晚期食道癌；紫杉醇联合顺铂化疗；临床疗效 [Abstract] objective：To investigate the clinical efficacy of paclitaxel combined with cisplatin chemotherapy in patients with advanced esophageal cancer.method：The control group was treated with cisplatin combined with 5- chemotherapy. The study group was treated with cisplatin plus paclitaxel. The clinical effect and adverse reaction of chemotherapy related adverse reactions were recorded in two groups of patients with advanced esophageal cancer.result：Two groups of patients with advanced esophageal cancer by the corresponding program after the completion of chemotherapy and research group，the total efficiency （75.56%）was significantly higher than that of the control group （55.56%）（P lt; 0.05）；group of chemotherapy related adverse reactions occurrence and control group contrast，no significant difference （P gt; 0.05）.Conclusion：Paclitaxel combined with cisplatin chemotherapy for patients with advanced esophageal cancer can significantly improve the clinical efficacy，which is conducive to the protection of the quality of life and life safety of patients. [Key words]：advanced esophageal cancer；paclitaxel combined with cisplatin chemotherapy；clinical efficacy 食道癌是临床常见及多发的食管上皮组织恶性肿瘤，晚期患者大多因错过最佳手术治疗时机而选择化学治疗[1]。本文为提高晚期食道癌临床疗效，特于2010年1月—2015年3月期间选取我院收治的此类患者（90例）作为研究对象，探讨晚期食道癌患者经紫杉醇联合顺铂化疗临床疗效，现总结如下。 1 资料与方法 1．1 一般资料 90例晚期食道癌患者中男56例、女34例，年龄40-78岁、平均（65.43plusmn;2.19）岁，临床分期：III期31例、IV期59例，病理分型：腺癌27例、鳞癌49例、腺鳞癌11例、小细胞癌3例。按照就诊序号（单、双）将90例晚期食道癌患者随机分为两组（研究组、对照组，每组n=45例），上述资料两组对比Pgt;0.05（无显著差异，有可比性）。 1．2 方法 1. 2. 1 治疗方法 对照组给予顺铂联合5-氟尿嘧啶化疗：初始1-3d。给予20mg/m2顺铂+100ml生理盐水静脉滴注，初始1-5d给予0.5mg/m25-氟尿嘧啶+5%、500ml葡萄糖注射